- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05619367
A Compassionate Use (CU) Program of Odronextamab
December 22, 2025 updated by: Regeneron Pharmaceuticals
Provide compassionate use of odronextamab
Study Overview
Status
Available
Conditions
Intervention / Treatment
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
November 8, 2022
First Submitted That Met QC Criteria
November 8, 2022
First Posted (Actual)
November 16, 2022
Study Record Updates
Last Update Posted (Estimated)
December 23, 2025
Last Update Submitted That Met QC Criteria
December 22, 2025
Last Verified
December 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Disease Attributes
- Immune System Diseases
- Neoplasms by Histologic Type
- Lymphatic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Pathological Conditions, Signs and Symptoms
- Hemic and Lymphatic Diseases
- Recurrence
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Follicular
Other Study ID Numbers
- R1979-Odronextamab
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diffuse Large B-Cell Lymphoma (DLBCL)
-
Memorial Sloan Kettering Cancer CenterSanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaboratorsActive, not recruitingDiffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)United States
-
Zhejiang Teruisi Pharmaceutical Inc.Not yet recruitingDiffuse Large B-Cell Lymphoma (DLBCL)China
-
Sun Yat-sen UniversityGuangdong Provincial Hospital of Traditional Chinese Medicine; Guangzhou First... and other collaboratorsRecruitingDiffuse Large B Cell Lymphoma (DLBCL)China
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaActive, not recruitingDiffuse Large B Cell Lymphoma (DLBCL)Italy
-
University Health Network, TorontoRecruitingDiffuse Large B Cell Lymphoma (DLBCL)Canada
-
Hoffmann-La RocheCompletedDiffuse Large B-Cell Lymphoma (DLBCL)United States
-
AmgenMerck Sharp & Dohme LLCCompletedRelapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)United States, Germany, Spain, Australia, Netherlands, France
-
Fondazione Italiana Linfomi ONLUSCompletedDiffuse Large B Cell Lymphoma (DLBCL) | Elderly Patients (>65 Years)Italy
-
Poseida Therapeutics, Inc.Roche-GenentechActive, not recruitingDLBCL, Diffused Large B Cell Lymphoma | DLBCL | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | High-grade B-cell Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | DLBCL Arising From Follicular Lymphoma | DLBCL NOS | Follicular Lymphoma Grade... and other conditionsUnited States
-
Liling ZhangRecruitingLymphoma | Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)China
Clinical Trials on Odronextamab
-
Gottfried von Keudell, MD PhDRegeneron PharmaceuticalsRecruiting
-
Regeneron PharmaceuticalsActive, not recruitingB-cell Non-Hodgkin Lymphoma (B-NHL)United States, Spain, Australia, France, Taiwan, Singapore, Japan, United Kingdom, China, Italy, Poland, Germany, South Korea, Canada
-
Regeneron PharmaceuticalsRecruitingLupus Nephritis (LN)United States, Taiwan, South Korea, Germany, Spain
-
Regeneron PharmaceuticalsRecruitingB-cell Non-Hodgkins Lymphoma (B-NHL)United States, United Kingdom, France, Spain, Netherlands
-
Regeneron PharmaceuticalsCompletedChronic Lymphocytic Leukemia | Non-Hodgkin LymphomaUnited States, United Kingdom, Germany, Israel, France
-
Regeneron PharmaceuticalsCompletedRelapsed/Refractory Aggressive B-Cell LymphomaUnited States, Spain, Israel, Germany, Poland, Austria
-
Joseph TuscanoNational Cancer Institute (NCI)RecruitingRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaUnited States
-
Regeneron PharmaceuticalsRecruitingRelapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)Australia, Italy, Taiwan, Spain, France, United Kingdom, Belgium, Austria, Israel, United States, Czechia, Poland, Brazil, Malaysia, Thailand, Germany, South Korea, Turkey (Türkiye)
-
Regeneron PharmaceuticalsActive, not recruitingFollicular Lymphoma (FL)United States, Spain, Brazil, France, Italy, Australia, Belgium, Taiwan, United Kingdom, Israel, Thailand, Austria, Poland, Germany, Chile, Czechia, Turkey (Türkiye)
-
Regeneron PharmaceuticalsRecruitingDiffuse Large B-cell Lymphoma (DLBCL)Austria, United States, Australia, Italy, Taiwan, Spain, Belgium, Singapore, Israel, Germany, France, Malaysia, United Kingdom, Thailand, Czechia, Chile, Ireland, Poland, South Korea, Turkey (Türkiye)